세계의 신경퇴행성 질환 시장 보고서(2025년)

Neurodegenerative Disease Global Market Report 2025

US $ 4,490 ￦ 6,312,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,124,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,936,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

신경퇴행성 질환 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 이러한 예상 성장은 유전자 및 세포 치료의 발전, 디지털 바이오마커의 사용 증가, 정밀 의학 전략의 증가, 질병 수정 의약품 파이프라인의 확대, 신경학 분야에서 인공 지능의 채택 확대에 기인합니다. 예측 기간 동안 예상되는 주목할 만한 동향으로는 신경 영상 기술의 발전, 첨단 뇌 표적 의약품 전달 시스템, 맞춤형 치료 혁신, 바이오마커 발견의 획기적인 발전, 유전자 편집 기술의 발전 등이 있습니다.

연구 및 임상 시험의 증가가 향후 신경퇴행성 질환 시장 성장을 촉진할 것으로 예상됩니다. 임상 시험은 새로운 치료법, 의약품 또는 의료 기기의 안전성, 효능 및 잠재적인 부작용을 평가하기 위해 인간을 대상으로 진행하는 연구를 의미합니다. 연구 및 임상 시험의 증가는 주로 진화하는 의료 요구를 충족하고 환자 치료 결과를 개선하기 위한 새로운 치료법에 대한 수요 증가에 의해 촉진되고 있습니다. 이러한 임상 시험은 새로운 치료법의 안전성과 유효성에 대한 필수 데이터를 생성하여 치료법 개발을 촉진하고 환자 치료를 개선함으로써 신경퇴행성 질환 연구에 중요한 역할을 합니다. 예를 들어, 2023년 11월에 영국 제약 산업 협회(ABPI)가 발표한 보고서에 따르면, 영국에서 연간 시작된 산업계 임상 시험의 총 수는 2021년 394건에서 2022년 411건으로 4.3% 소폭 증가했습니다. 따라서 연구 및 임상 시험의 증가는 신경퇴행성 질환 시장의 성장을 촉진할 것으로 예상됩니다.

신경퇴행성 질환 시장에서 사업을 전개하는 주요 기업들은 치료의 정확성을 개선하고, 질병 수정 효과를 강화하며, 환자의 삶의 질을 높이기 위해 차세대 적응형 심부 뇌 자극(aDBS) 시스템과 같은 혁신적인 제품 개발에 주력하고 있습니다. 차세대 적응형 심부 뇌 자극(aDBS) 시스템은 신경 피드백을 기반으로 자극 파라미터를 동적으로 조정하여 파킨슨병에 대한 실시간 맞춤형 치료를 제공하는 고급 신경 자극 장치입니다. 이는 치료 효과를 최적화하고 부작용을 최소화하여 환자 결과를 개선합니다. 예를 들어, 2025년 2월, 미국 의료 기술 기업인 메드트로닉은 파킨슨병을 위한 세계 최초의 적응형 심부 뇌 자극(aDBS) 시스템에 대해 미국 식품의약국(USFDA)의 승인을 받았습니다. 이 승인은 BrainSense 기술을 탑재한 Percept RC 신경 자극기의 사전 시장 승인(PMA) 신청을 포함합니다. 이 시스템은 환자의 뇌 신호에 따라 치료를 자동으로 조정하며, 진행성 파킨슨병 환자의 증상 완화에 임상적으로 검증되었으며, 개인 맞춤형 신경 조절 치료 분야의 주요 진전을 상징합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 신경퇴행성 질환 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 신경퇴행성 질환 시장 : 성장률 분석
• 세계의 신경퇴행성 질환 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 신경퇴행성 질환 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 신경퇴행성 질환 : 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 신경퇴행성 질환 시장 : 질환 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 파킨슨병
• 알츠하이머병
• 다발성 경화증
• 헌팅턴병
• 근위축성 측삭 경화증
• 세계의 신경퇴행성 질환 시장 : 약제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• N-메틸-D-아스파르트산 수용체 길항제
• 콜린에스테라아제 억제제
• 도파민 작용제
• 면역 조절제
• 아세틸콜린에스테라아제(AChE) 억제제
• 길항제, 모노아민 산화 효소 B(MAO-B) 억제제
• 카테콜-O-메틸트랜스퍼라제(COMT) 억제제
• 선택적 세로토닌 재 흡수 억제제(SSRI)
• 기타 약물의 유형
• 세계의 신경퇴행성 질환 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 경구
• 주사제
• 경피
• 기타 투여 경로
• 세계의 신경퇴행성 질환 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타 유통 채널
• 세계의 신경퇴행성 질환 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 소매
• 온라인
• 세계의 신경퇴행성 질환 시장 : 파킨슨병 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 특발성 파킨슨병
• 가족성 파킨슨병
• 조기 발병 파킨슨병
• 파킨슨병
• 세계의 신경퇴행성 질환 시장 : 알츠하이머병 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 조기 발병형 알츠하이머병
• 만발성 알츠하이머병
• 가족성 알츠하이머병(FAD)
• 염증성 아형
• 비염증성 아형
• 피질 아형
• 세계의 신경퇴행성 질환 시장 : 다발성 경화증(MS) 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 임상적으로 고립된 증후군(CIS)
• 재발 관해형 다발성 경화증(RRMS)
• 2차 진행성 다발성 경화증(SPMS)
• 원발성 진행성 다발성 경화증(PPMS)
• 진행성 재발성 다발성 경화증(PRMS)
• 세계의 신경퇴행성 질환 시장 : 헌팅턴병 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 성인 발병 헌팅턴병
• 청소년 헌팅턴병
• 세계의 신경퇴행성 질환 시장 : 근위축성 측삭 경화증(ALS) 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 클래식 ALS
• 사지 발병형 ALS
• 구마비형 ALS
• 호흡기 발병형 ALS
• 원발성 측삭 경화증(PLS)
• 진행성 근위축증(PMA)
• 청소년 ALS
• ALS-파킨슨병-치매 복합체(ALS-PDC)

제7장 지역별, 국가별 분석

• 세계의 신경퇴행성 질환 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 신경퇴행성 질환 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 신경퇴행성 질환 시장 : 경쟁 구도
• 신경퇴행성 질환 시장 : 기업 프로파일
  • Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
  • F. Hoffmann-La Roche Ltd : 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Novartis AG
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Merck & Co. Inc.
• Biogen Inc.
• Neurocrine Biosciences Inc.
• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Cassava Sciences Inc.
• Denali Therapeutics Inc.
• Voyager Therapeutics Inc.
• AC Immune SA
• Amylyx Pharmaceuticals Inc.
• Sage Therapeutics Inc.
• Alzheon Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 신경퇴행성 질환 시장(2029년) : 새로운 기회를 제공하는 국가
• 신경퇴행성 질환 시장(2029년) : 새로운 기회를 제공하는 부문
• 신경퇴행성 질환 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

HBR

영문 목차

영문목차

Neurodegenerative disease encompasses a group of disorders marked by the progressive deterioration of the structure and function of the nervous system, including the brain and spinal cord. The primary objective in this field is to understand, diagnose, and treat these conditions through advancements in biotechnology, pharmaceuticals, and medical technology. The aim is to slow disease progression, enhance patient outcomes, and lessen the burden on healthcare systems. This field also supports aging populations, improves neurological care, and contributes to a sustainable, technology-driven healthcare infrastructure.

The main types of neurodegenerative diseases include Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis. Parkinson's disease is a progressive neurological condition that impairs movement control due to the degeneration of dopamine-producing brain cells. These conditions are managed using various drug types such as N-methyl-D-aspartate (NMDA) receptor antagonists, cholinesterase inhibitors, dopamine agonists, and immunomodulatory drugs. Administration routes include oral, injectable, transdermal, and other methods. The drugs are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels. Key end-users include hospitals, retail providers, and online platforms.

The neurodegenerative diseases market research report is one of a series of new reports from The Business Research Company that provides neurodegenerative diseases market statistics, including the neurodegenerative diseases industry global market size, regional shares, competitors with the neurodegenerative diseases market share, detailed neurodegenerative diseases market segments, market trends, and opportunities, and any further data you may need to thrive in the neurodegenerative diseases industry. This neurodegenerative diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurodegenerative disease market size has grown strongly in recent years. It will grow from $52.30 billion in 2024 to $57.23 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. Growth in the historic period was driven by enhanced diagnostic capabilities, increased demand for symptomatic treatments, more clinical trial activity, strengthened public-private partnerships, and a growing burden of unmet medical needs.

The neurodegenerative disease market size is expected to see strong growth in the next few years. It will grow to $81.23 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. This anticipated growth is attributed to advancements in gene and cell therapy, increased use of digital biomarkers, a rise in precision medicine strategies, expansion of disease-modifying drug pipelines, and greater adoption of artificial intelligence in neurology. Notable trends expected during the forecast period include progress in neuroimaging technologies, advanced brain-targeted drug delivery systems, personalized treatment innovations, biomarker discovery breakthroughs, and advancements in gene editing techniques.

The increase in research and clinical trials is expected to propel the growth of the neurodegenerative disease market going forward. Clinical trials refer to research studies conducted with human participants to evaluate the safety, efficacy, and potential side effects of new treatments, drugs, or medical devices. The rise in research and clinical trials is primarily driven by the growing demand for new treatments to meet evolving healthcare needs and enhance patient outcomes. These trials play a crucial role in neurodegenerative disease research by generating essential data on the safety and effectiveness of new therapies, thereby advancing therapeutic development and improving patient care. For instance, in November 2023, according to a report published by the Association of the British Pharmaceutical Industry (ABPI), a UK-based association, the total number of industry clinical trials initiated annually in the UK rose slightly by 4.3%, from 394 trials in 2021 to 411 in 2022. Therefore, the increase in research and clinical trials is expected to drive the growth of the neurodegenerative disease market.

Major companies operating in the neurodegenerative disease market are focusing on developing innovative products such as next-generation adaptive Deep Brain Stimulation (aDBS) systems, aiming to improve treatment precision, enhance disease-modifying effects, and increase patient quality of life. Next-generation adaptive deep brain stimulation (aDBS) systems are advanced neurostimulation devices designed to deliver real-time, personalized treatment for Parkinson's disease by dynamically adjusting stimulation parameters based on neural feedback. This optimizes therapeutic effects and minimizes side effects, resulting in better patient outcomes. For example, in February 2025, Medtronic, a US-based medical technology company, received approval from the U.S. Food and Drug Administration (USFDA) for the world's first adaptive deep brain stimulation (aDBS) system for Parkinson's disease. This approval covers the premarket approval (PMA) application for the Percept RC neurostimulator with BrainSense technology, which automatically adjusts therapy in response to a patient's brain signals. The system is clinically validated to provide symptom relief for advanced Parkinson's disease patients and represents a major advancement in personalized neuromodulation therapies.

In December 2024, AbbVie, a US-based biopharmaceutical company, acquired Aliada Therapeutics for an undisclosed amount. Through this acquisition, AbbVie aims to advance potentially disease-modifying therapies for Alzheimer's disease and enhance its neuroscience pipeline by utilizing Aliada's innovative drug delivery platform capable of crossing the blood-brain barrier. Aliada Therapeutics is a US-based company that develops precision medicines for neurological disorders.

Major players in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.

North America was the largest region in the neurodegenerative disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neurodegenerative disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurodegenerative disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurodegenerative disease market consists of revenues earned by entities through services such as biotechnology research, pharmaceutical development, diagnostic solutions, medical technologies, and patient care advancements aimed at understanding, diagnosing, and treating neurodegenerative conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurodegenerative disease market also includes sales of pharmaceuticals, biotechnology treatments, medical devices, and diagnostic tools aimed at managing and treating neurodegenerative conditions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurodegenerative Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurodegenerative disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurodegenerative disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurodegenerative disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Parkinson's Disease; Alzheimer's Disease; Multiple Sclerosis; Huntington Disease; Amyotrophic Lateral Sclerosis
• 2) By Drug Type: N-methyl-D-aspartate Receptor antagonists; Cholinesterase Inhibitors; Dopamine Agonists; Immunomodulatory Drugs; Acetylcholinesterase (AChE) Inhibitors; Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor; Catechol-O-Methyltransferase (COMT) Inhibitor; Selective Serotonin Reuptake Inhibitor (SSRIs); Other Drug Types
• 3) By Route of Administration: Oral; Injectable; Transdermal; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 5) By End-User: Hospital; Retail; Online
• Subsegment:
• 1) By Parkinson's Disease: Idiopathic Parkinson's Disease; Familial Parkinson's Disease; Early-Onset Parkinson's Disease; Parkinsonism
• 2) By Alzheimer's Disease: Early-Onset Alzheimer's Disease; Late-Onset Alzheimer's Disease; Familial Alzheimer's Disease (FAD); Inflammatory Subtype; Non-Inflammatory Subtype; Cortical Subtype
• 3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS); Relapsing-Remitting MS (RRMS); Secondary Progressive MS (SPMS); Primary Progressive MS (PPMS); Progressive-Relapsing MS (PRMS)
• 4) By Huntington's Disease: Adult-Onset Huntington's Disease; Juvenile Huntington's Disease
• 5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS; Limb-Onset ALS; Bulbar-Onset ALS; Respiratory-Onset ALS; Primary Lateral Sclerosis (PLS); Progressive Muscular Atrophy (PMA); Juvenile ALS; ALS-Parkinsonism-Dementia Complex (ALS-PDC)
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurodegenerative Disease Market Characteristics

3. Neurodegenerative Disease Market Trends And Strategies

4. Neurodegenerative Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Neurodegenerative Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neurodegenerative Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neurodegenerative Disease Market Growth Rate Analysis
• 5.4. Global Neurodegenerative Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neurodegenerative Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neurodegenerative Disease Total Addressable Market (TAM)

6. Neurodegenerative Disease Market Segmentation

• 6.1. Global Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parkinson's Disease
• Alzheimer's Disease
• Multiple Sclerosis
• Huntington Disease
• Amyotrophic Lateral Sclerosis
• 6.2. Global Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• N-methyl-D-aspartate Receptor antagonists
• Cholinesterase Inhibitors
• Dopamine Agonists
• Immunomodulatory Drugs
• Acetylcholinesterase (AChE) Inhibitors
• Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
• Catechol-O-Methyltransferase (COMT) Inhibitor
• Selective Serotonin Reuptake Inhibitor (SSRIs)
• Other Drug Types
• 6.3. Global Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Transdermal
• Other Routes Of Administration
• 6.4. Global Neurodegenerative Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.5. Global Neurodegenerative Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Retail
• Online
• 6.6. Global Neurodegenerative Disease Market, Sub-Segmentation Of Parkinson's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Idiopathic Parkinson's Disease
• Familial Parkinson's Disease
• Early-Onset Parkinson's Disease
• Parkinsonism
• 6.7. Global Neurodegenerative Disease Market, Sub-Segmentation Of Alzheimer's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early-Onset Alzheimer's Disease
• Late-Onset Alzheimer's Disease
• Familial Alzheimer's Disease (FAD)
• Inflammatory Subtype
• Non-Inflammatory Subtype
• Cortical Subtype
• 6.8. Global Neurodegenerative Disease Market, Sub-Segmentation Of Multiple Sclerosis (MS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinically Isolated Syndrome (CIS)
• Relapsing-Remitting MS (RRMS)
• Secondary Progressive MS (SPMS)
• Primary Progressive MS (PPMS)
• Progressive-Relapsing MS (PRMS)
• 6.9. Global Neurodegenerative Disease Market, Sub-Segmentation Of Huntington's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult-Onset Huntington's Disease
• Juvenile Huntington's Disease
• 6.10. Global Neurodegenerative Disease Market, Sub-Segmentation Of Amyotrophic Lateral Sclerosis (ALS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classical ALS
• Limb-Onset ALS
• Bulbar-Onset ALS
• Respiratory-Onset ALS
• Primary Lateral Sclerosis (PLS)
• Progressive Muscular Atrophy (PMA)
• Juvenile ALS
• ALS-Parkinsonism-Dementia Complex (ALS-PDC)

7. Neurodegenerative Disease Market Regional And Country Analysis

• 7.1. Global Neurodegenerative Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neurodegenerative Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurodegenerative Disease Market

• 8.1. Asia-Pacific Neurodegenerative Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurodegenerative Disease Market

• 9.1. China Neurodegenerative Disease Market Overview
• 9.2. China Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurodegenerative Disease Market

• 10.1. India Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurodegenerative Disease Market

• 11.1. Japan Neurodegenerative Disease Market Overview
• 11.2. Japan Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurodegenerative Disease Market

• 12.1. Australia Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurodegenerative Disease Market

• 13.1. Indonesia Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurodegenerative Disease Market

• 14.1. South Korea Neurodegenerative Disease Market Overview
• 14.2. South Korea Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurodegenerative Disease Market

• 15.1. Western Europe Neurodegenerative Disease Market Overview
• 15.2. Western Europe Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurodegenerative Disease Market

• 16.1. UK Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurodegenerative Disease Market

• 17.1. Germany Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurodegenerative Disease Market

• 18.1. France Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurodegenerative Disease Market

• 19.1. Italy Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurodegenerative Disease Market

• 20.1. Spain Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurodegenerative Disease Market

• 21.1. Eastern Europe Neurodegenerative Disease Market Overview
• 21.2. Eastern Europe Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurodegenerative Disease Market

• 22.1. Russia Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurodegenerative Disease Market

• 23.1. North America Neurodegenerative Disease Market Overview
• 23.2. North America Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurodegenerative Disease Market

• 24.1. USA Neurodegenerative Disease Market Overview
• 24.2. USA Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurodegenerative Disease Market

• 25.1. Canada Neurodegenerative Disease Market Overview
• 25.2. Canada Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurodegenerative Disease Market

• 26.1. South America Neurodegenerative Disease Market Overview
• 26.2. South America Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurodegenerative Disease Market

• 27.1. Brazil Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurodegenerative Disease Market

• 28.1. Middle East Neurodegenerative Disease Market Overview
• 28.2. Middle East Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurodegenerative Disease Market

• 29.1. Africa Neurodegenerative Disease Market Overview
• 29.2. Africa Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurodegenerative Disease Market Competitive Landscape And Company Profiles

• 30.1. Neurodegenerative Disease Market Competitive Landscape
• 30.2. Neurodegenerative Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Neurodegenerative Disease Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Eli Lilly and Company
• 31.4. Merck & Co. Inc.
• 31.5. Biogen Inc.
• 31.6. Neurocrine Biosciences Inc.
• 31.7. Alnylam Pharmaceuticals Inc.
• 31.8. Ionis Pharmaceuticals Inc.
• 31.9. Cassava Sciences Inc.
• 31.10. Denali Therapeutics Inc.
• 31.11. Voyager Therapeutics Inc.
• 31.12. AC Immune SA
• 31.13. Amylyx Pharmaceuticals Inc.
• 31.14. Sage Therapeutics Inc.
• 31.15. Alzheon Inc.

32. Global Neurodegenerative Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurodegenerative Disease Market

34. Recent Developments In The Neurodegenerative Disease Market

35. Neurodegenerative Disease Market High Potential Countries, Segments and Strategies

• 35.1 Neurodegenerative Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neurodegenerative Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neurodegenerative Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료